• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝纤维化和肝硬化逆转的组织病理学评估。

Histopathological evaluation of liver fibrosis and cirrhosis regression.

机构信息

Department of Pathology and State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.

Department of Pathology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.

出版信息

Clin Mol Hepatol. 2017 Dec;23(4):302-307. doi: 10.3350/cmh.2017.0078. Epub 2017 Dec 20.

DOI:10.3350/cmh.2017.0078
PMID:29281870
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5760001/
Abstract

The hepatic repair complex in the setting of cirrhosis has received increasing attention, as it implies the regression of cirrhosis, which was traditionally taken to be an irreversible state. In this brief review, the patterns of fibrosis, the existing staging systems for chronic liver disease and the histopathological features of cirrhosis regression are discussed.

摘要

在肝硬化的背景下，肝脏修复复合物受到了越来越多的关注，因为它意味着肝硬化的消退，而肝硬化在传统上被认为是一种不可逆转的状态。在这篇简短的综述中，讨论了纤维化模式、现有的慢性肝病分期系统以及肝硬化消退的组织病理学特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6361/5760001/f02a5a1eb09c/cmh-2017-0078f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6361/5760001/bb51bffe2ad9/cmh-2017-0078f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6361/5760001/1c7f20647a59/cmh-2017-0078f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6361/5760001/f02a5a1eb09c/cmh-2017-0078f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6361/5760001/bb51bffe2ad9/cmh-2017-0078f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6361/5760001/1c7f20647a59/cmh-2017-0078f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6361/5760001/f02a5a1eb09c/cmh-2017-0078f3.jpg

相似文献

1
Histopathological evaluation of liver fibrosis and cirrhosis regression.肝纤维化和肝硬化逆转的组织病理学评估。
Clin Mol Hepatol. 2017 Dec;23(4):302-307. doi: 10.3350/cmh.2017.0078. Epub 2017 Dec 20.
2
Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al.肝硬化的逆转：在 Wanless 等人的开创性文章发表 18 年后的最新进展
Virchows Arch. 2018 Jul;473(1):15-22. doi: 10.1007/s00428-018-2340-2. Epub 2018 Mar 27.
3
Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B.长期使用拉米夫定治疗可使慢性乙型肝炎患者的晚期肝纤维化/肝硬化病情出现好转。
J Gastroenterol Hepatol. 2015 Feb;30(2):372-8. doi: 10.1111/jgh.12718.
4
[Reversibility of hepatic fibrosis].[肝纤维化的可逆性]
Ned Tijdschr Geneeskd. 2014;158:A6790.
5
Development and Regression of Cirrhosis.肝硬化的发展与消退
Dig Dis. 2016;34(4):374-81. doi: 10.1159/000444550. Epub 2016 May 11.
6
[Role of liver biopsy in the assessment of hepatic fibrosis--its utility and limitations].[肝活检在肝纤维化评估中的作用——其效用与局限性]
Korean J Hepatol. 2007 Jun;13(2):138-45.
7
Evolving strategies for liver fibrosis staging: Non-invasive assessment.肝纤维化分期的不断发展策略：非侵入性评估
World J Gastroenterol. 2017 Jan 14;23(2):191-196. doi: 10.3748/wjg.v23.i2.191.
8
Non-invasive markers and predictors of severity of hepatic fibrosis in HCV patients at Sharkia Governorate, Egypt.埃及谢赫村省丙型肝炎病毒患者肝纤维化严重程度的非侵入性标志物及预测指标
J Egypt Soc Parasitol. 2004 Apr;34(1 Suppl):459-78.
9
Cirrhosis--can we reverse hepatic fibrosis?肝硬化——我们能否逆转肝纤维化？
Eur J Surg Suppl. 2002(587):100-12.
10
Practical Guide, Challenges, and Pitfalls in Liver Fibrosis Staging.实用指南、挑战与肝纤维化分期中的陷阱。
Surg Pathol Clin. 2023 Sep;16(3):457-472. doi: 10.1016/j.path.2023.04.002. Epub 2023 Jun 4.

引用本文的文献

1
The Impact of Hybrid Bionanomaterials Based on Gold Nanoparticles on Liver Injury in an Experimental Model of Thioacetamide-Induced Hepatopathy.基于金纳米颗粒的杂化生物纳米材料对硫代乙酰胺诱导的肝病实验模型中肝损伤的影响
Biomolecules. 2025 Jul 24;15(8):1068. doi: 10.3390/biom15081068.
2
Taurochenodeoxycholic acid as a sensitive stratification marker for HBV-associated hepatic cirrhosis status has a hepatoprotective effect.牛磺鹅去氧胆酸作为乙肝相关肝硬化状态的敏感分层标志物具有肝脏保护作用。
Sci Rep. 2025 Aug 20;15(1):30547. doi: 10.1038/s41598-025-16348-z.
3
Simple Clinical Prediction Rules for Identifying Significant Liver Fibrosis: Evaluation of Established Scores and Development of the Aspartate Aminotransferase-Thrombocytopenia-Albumin (ATA) Score.

本文引用的文献

1
Mechanisms of hepatic stellate cell activation.肝星状细胞激活的机制。
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411. doi: 10.1038/nrgastro.2017.38. Epub 2017 May 10.
2
On beyond staging and grading: Liver biopsy evaluation in a posttreatment world.超越分期与分级：治疗后世界中的肝活检评估
Hepatology. 2017 May;65(5):1432-1434. doi: 10.1002/hep.29111. Epub 2017 Mar 30.
3
Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.赖氨酸氧化酶样蛋白2（LOXL2）的选择性靶向作用可抑制肝纤维化进展并加速其逆转。
用于识别显著肝纤维化的简单临床预测规则：对既定评分的评估及天冬氨酸氨基转移酶-血小板减少-白蛋白（ATA）评分的制定
Diagnostics (Basel). 2025 Apr 28;15(9):1119. doi: 10.3390/diagnostics15091119.
4
Noninvasive diagnosis of significant liver fibrosis in patients with chronic hepatitis B using nomogram and machine learning models.使用列线图和机器学习模型对慢性乙型肝炎患者的显著肝纤维化进行无创诊断。
Sci Rep. 2025 Jan 2;15(1):571. doi: 10.1038/s41598-024-85012-9.
5
Liver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives.肝纤维化导致肝硬化：基本机制与临床展望。
Biomedicines. 2024 Sep 30;12(10):2229. doi: 10.3390/biomedicines12102229.
6
Application of liver biopsy in etiological diagnosis of unexplained portal hypertension: Porto-sinusoidal vascular disease should not be ignored.肝活检在不明原因门静脉高压病因诊断中的应用：门体静脉血管病变不容忽视。
Medicine (Baltimore). 2024 Sep 27;103(39):e39819. doi: 10.1097/MD.0000000000039819.
7
Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells.肝纤维化：从基础科学到临床进展，聚焦于肝星状细胞的核心作用。
Int J Mol Sci. 2024 Jul 18;25(14):7873. doi: 10.3390/ijms25147873.
8
Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?营养保健品能否支持 MASLD/MASH 的治疗，从而影响肝纤维化的进程？
Int J Mol Sci. 2024 May 11;25(10):5238. doi: 10.3390/ijms25105238.
9
Oxidative stress promotes liver fibrosis by modulating the microRNA-144 and SIN3A-p38 pathways in hepatic stellate cells.氧化应激通过调节肝星状细胞中的 microRNA-144 和 SIN3A-p38 通路促进肝纤维化。
Int J Biol Sci. 2024 Apr 8;20(7):2422-2439. doi: 10.7150/ijbs.92749. eCollection 2024.
10
Microbiological Characteristics and Antibiotic Sensitivity in Patients with Nosocomial Spontaneous Bacterial Peritonitis Caused by : A Multicenter Study.由……引起的医院获得性自发性细菌性腹膜炎患者的微生物学特征及抗生素敏感性：一项多中心研究
Infect Microbes Dis. 2020 Aug 7;2(4):167-172. doi: 10.1097/IM9.0000000000000035. eCollection 2020 Dec.
Gut. 2017 Sep;66(9):1697-1708. doi: 10.1136/gutjnl-2016-312473. Epub 2017 Jan 10.
4
New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment.慢性乙型肝炎患者治疗前后肝活检纤维化评估的新分类。
Hepatology. 2017 May;65(5):1438-1450. doi: 10.1002/hep.29009. Epub 2017 Mar 22.
5
Mechanisms of liver fibrosis resolution.肝纤维化消退的机制。
J Hepatol. 2015 Oct;63(4):1038-9. doi: 10.1016/j.jhep.2015.03.039. Epub 2015 Jul 29.
6
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.肥胖症手术可减轻病态肥胖患者非酒精性脂肪性肝炎的特征。
Gastroenterology. 2015 Aug;149(2):379-88; quiz e15-6. doi: 10.1053/j.gastro.2015.04.014. Epub 2015 Apr 25.
7
Congestive hepatic fibrosis score: a novel histologic assessment of clinical severity.充血性肝纤维化评分：临床严重程度的一种新型组织学评估方法。
Mod Pathol. 2014 Dec;27(12):1552-8. doi: 10.1038/modpathol.2014.79. Epub 2014 Jun 13.
8
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎时肝硬化的逆转：一项 5 年开放标签随访研究。
Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10.
9
The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis.Laennec 分期系统用于肝硬化的组织学亚分类，有助于对肝硬化患者的预后进行分层。
J Hepatol. 2012 Sep;57(3):556-63. doi: 10.1016/j.jhep.2012.04.029. Epub 2012 May 19.
10
Clinical evidence for the regression of liver fibrosis.临床证据表明肝纤维化可逆转。
J Hepatol. 2012 May;56(5):1171-1180. doi: 10.1016/j.jhep.2011.09.024. Epub 2012 Jan 13.